- Yunnan Baiyao’s fiscal year net income missed estimates.
- The net income stood at 4.09 billion yuan.
- This was lower than the estimated 4.72 billion yuan.
- The revenue reported was 39.11 billion yuan.
- The estimated revenue was higher, at 39.95 billion yuan.
- There were 19 buys and 1 hold on the stock, with no sells.
A look at Yunnan Baiyao Group Co., Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 5 | |
| Growth | 5 | |
| Resilience | 4 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 4.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Yunnan Baiyao Group Co., Ltd. is a traditional Chinese medicine company that has been making waves in the market with its strong performance. The company has received an overall score of 4 out of 5 on the Smartkarma Smart Scores, indicating a positive long-term outlook. With a score of 5 for both dividend and growth, investors can expect consistent returns and potential for future expansion. Additionally, the company has a strong resilience score of 4, indicating its ability to withstand market fluctuations and remain profitable. Its momentum score of 4 also suggests that the company is on a steady upward trajectory. Overall, Yunnan Baiyao Group Co. is a promising player in the traditional Chinese medicine market and has the potential for long-term growth and stability.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
